Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

SOPHiA GENETICS (SOPH) Research & Development (2020 - 2025)

SOPHiA GENETICS's Research & Development history spans 6 years, with the latest figure at -$8.5 million for Q4 2025.

  • On a quarterly basis, Research & Development rose 6.62% to -$8.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$34.2 million, a 0.44% change, with the full-year FY2025 number at -$34.2 million, changed 0.44% from a year prior.
  • Research & Development hit -$8.5 million in Q4 2025 for SOPHiA GENETICS, down from -$8.1 million in the prior quarter.
  • Over the last five years, Research & Development for SOPH hit a ceiling of -$6.2 million in Q1 2021 and a floor of -$10.1 million in Q3 2022.
  • Historically, Research & Development has averaged -$8.4 million across 5 years, with a median of -$8.7 million in 2023.
  • Biggest five-year swings in Research & Development: soared 99.85% in 2021 and later tumbled 53.32% in 2022.
  • Tracing SOPH's Research & Development over 5 years: stood at -$6.4 million in 2021, then dropped by 6.79% to -$6.8 million in 2022, then crashed by 43.73% to -$9.8 million in 2023, then rose by 6.31% to -$9.1 million in 2024, then rose by 6.62% to -$8.5 million in 2025.
  • Business Quant data shows Research & Development for SOPH at -$8.5 million in Q4 2025, -$8.1 million in Q3 2025, and -$8.5 million in Q2 2025.